“The future is very bright with opportunities for disruptive therapies that can treat so many patients.”
Bob Wynalek
Executive & Board Director at DiscGenics, Inc.
Bob Wynalek is the Chief Operating Officer, Chief Commercialization Officer, and Board Director at DiscGenics, Inc. He is a medical device and biopharma professional and entrepreneur with 35 years experience within the Regenerative Medicine, Spine, Neurosurgical, and Orthopedic markets.
Mr. Wynalek has successfully built and re-built organizations, inclusive of experience with early stage organizations. Executive and functional leadership experience in general management, sales, marketing, product development, business development, clinical, and operations disciplines.
Leading the regenerative cell therapy space with new, innovative solutions.
Find out about DiscGenics and our mission of improving the lives of those debilitated by degenerative diseases of the spine.
Bob Wynalek is a skilled medical device and biologics executive with 40 years of experience in the orthopedic, spinal and neurosurgical markets. He joined DiscGenics, where he is now the Chief Operating and Commercialization Officer, in 2010. Prior to that, Mr. Wynalek was the President of domestic business for Osteotech, Inc. where he oversaw development, regulatory clearance and commercialization of numerous biologic devices for bone healing. Osteotech, Inc. was acquired by Medtronic, Inc. in 2010. Mr. Wynalek currently serves as a committee member of the Alliance for Regenerative Medicine and BioUtah.
“Regenerative medicine is the holy grail solution for many patients.”
